2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 229

Uric Acid and Incident Dementia over 10 Years
Abstract Number: 230

Serum Uric Acid As Short Term Mortality Predictor in the Acute Care Setting
Abstract Number: 231

Uric Acid Levels Predict Mortality in Women
Abstract Number: 232

Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis
Abstract Number: 233

Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis
Abstract Number: 234

Weight Variables and Their Association with Serum Urate Concentrations and Hyperuricemia in Young Adults
Abstract Number: 235

Relationship Between Tissue Stress during Gait and Patterns of Urate Deposition and Bone Erosion in Gout: A Biomechanical Computational Modelling Study
Abstract Number: 236

Foot and Ankle Muscle Strength in People with Gout: A Two-Arm Cross-Sectional Study
Abstract Number: 237

The Prevalence of Chondrocalcinosis of the Symphysis Pubis on CT Scan and Correlation with Calcium Pyrophosphate Dihydrate Crystal Deposition Disease
Abstract Number: 238

Relationship Between Ultrasonographic Synovial Inflammation and Ultrasonographic Urate Deposition Findings in Patients with Gout
Abstract Number: 239

The Role of Dual Energy Computed Tomography in Diagnosing Acute Gouty Arthritis: Comparison with Ultrasound and Aspiration
Abstract Number: 240

Volumetric Assessment of Tophaceous Gout
Abstract Number: 241

Inflammatory Syndrome in Polyarticular Gout – Description of a Previously Neglected Entity
Abstract Number: 242

Higher Serum Uric Acid Levels Are Associated with an Increased Risk of Flares: A Systematic Review
Abstract Number: 243

Increase in Risk of Future Attacks in Patients with Incident Gout: A Population-Based Study over 20 Years

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].